Krystal Biotech's 15-min chart sees a KDJ Golden Cross and Bullish Marubozu

Based on Krystal Biotech's 15-minute chart, a Golden Cross has been observed, accompanied by a Bullish Marubozu at 05/27/2025 14:00. This indicates a shift in momentum towards an upward trend, with the potential for further price appreciation. The dominance of buyers in the market suggests that bullish momentum is likely to persist.

Abeona Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (pz-cel), marking a significant milestone in the treatment of recessive dystrophic epidermolysis bullosa (RDEB). This approval positions Abeona as an emerging player in the dystrophic epidermolysis bullosa market [1].

RDEB is a severe, inherited skin disorder characterized by skin fragility due to the absence, deficiency, or malfunction of proteins critical to maintaining skin structure. The condition is particularly challenging to manage, with current treatments focusing on supportive care such as wound care, pain management, and infection prevention [1].

ZEVASKYN is the first and only FDA-approved autologous, gene-modified cell therapy for treating wounds in both adult and pediatric patients with RDEB. The approval was based on the results of the Phase III VIITAL study (NCT04227106), which demonstrated significant wound healing and pain reduction [1]. This therapy represents a significant advancement, as it offers a single application solution for RDEB wounds, which typically require multiple treatments.

The approval of ZEVASKYN is expected to become available in Q3 2025 through specialized facilities across the U.S., known as ZEVASKYN Qualified Treatment Centers (QTCs). These centers will ensure broad patient access to this innovative treatment [1].

The dystrophic epidermolysis bullosa market is poised for significant growth, driven by increasing prevalence, patient awareness, and a robust clinical pipeline. As of 2023, the market size in the 7MM (United States, European Union, and Japan) is estimated to be USD 550 million, with the market expected to grow at a significant Compound Annual Growth Rate (CAGR) by 2034 [2].

Abeona's ZEVASKYN approval is a testament to the advancements in gene therapy and cell-based treatments, offering new standards of care for patients with RDEB. The approval also highlights the potential for these innovative therapies to transform the market landscape, unlocking opportunities for medical innovation and economic growth.

References:
[1] https://www.prnewswire.com/news-releases/zevaskyn-approval-positions-abeona-as-emerging-player-in-dystrophic-epidermolysis-bullosa-market--delveinsight-302462822.html
[2] https://www.delveinsight.com/market-reports/dystrophic-epidermolysis-bullosa-market-insights-epidemiology-and-market-forecast-2034